Predicting serum phosphate levels in very preterm infants using machine learning.

Background: Hypophosphatemia in very preterm and small for gestational age (SGA) infants is common and associated with serious complications. Diagnosis relies on phosphate concentrations, measured in serum or plasma. Machine learning (ML) may enable indirect estimation of serum phosphate based on routinely collected clinical data and results from blood gas analysis. Objectives: To (1) describe first week electrolyte trajectories in the ImNuT-trial (Clinicaltrials.gov ID: NCT03555019), and (2) develop and externally validate ML models to estimate serum phosphate levels during the first postnatal week in very preterm infants, using routinely collected clinical and nutritional data. Methods: We performed a retrospective analysis of 120 infants born <29 weeks' gestation, all managed under a standardized nutritional protocol. Electrolyte trajectories (calcium, potassium, sodium, phosphate) were described using daily means stratified by hypophosphatemia and SGA status. For ML, we defined three regression tasks: concurrent phosphate prediction at blood gas analysis, and forecasts 12 h and 24 h ahead. Twenty-two candidate predictors from blood gases, anthropometry, SGA status and nutrient intakes were subjected to RENT-based variable selection within leave-one-group-out cross-validation. Multiple algorithms (elastic net, gradient boosting, random forests, k-nearest neighbours, kernel ridge, XGBoost) were trained under three preprocessing strategies (complete cases, complete cases without outliers, imputed data). Performance was evaluated with RMSE and Results: Among 119 infants with phosphate measurements (607 samples), 33.6% developed hypophosphatemia in week one. SGA infants had a markedly higher and earlier risk of hypophosphatemia compared to appropriate-for-gestational-age infants (log-rank Conclusions: SGA status is a major determinant of early hypophosphatemia risk in very preterm infants. ML models using routinely available clinical and nutritional data can moderately but consistently estimate serum phosphate levels, including 12-24 h ahead, and may serve as screening tools to guide nutritional management and reduce unnecessary blood sampling. Prospective validation is warranted before clinical implementation.